Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Daniel Nusser schreibt Kaufberatungen zu verschiedenen Themen, von der Unterhaltungselektronik bis zu Haushaltsgeräten. Insgeheim wartet er aber darauf, dass der Replikator aus Star Trek alles ...
Hosted on MSN22d
Regeneron CEO: We have 40 drugs in developmentIn an interview on CNBC’s Mad Money, Len Schleifer said Regeneron (REGN) currently has 40 drugs in development representing billions in potential sales. “We know how to make and develop drugs ...
By Theodore Schleifer and Mike Isaac Mark Zuckerberg, the Meta chief executive who has tried to keep a distance from politics, is warming to President-elect Donald J. Trump. Mr. Zuckerberg is ...
An agreement offers Gazans at least some respite, and for Israelis it means the release of hostages. But the deal’s ambiguity leaves open the possibility that fighting could resume within weeks ...
CEO Len Schleifer, M.D., Ph.D., was asked about disappointing sales of high-dose Eylea. “I’d be happier to talk about the pipeline,” Schleifer said. Earlier on Monday, Regeneron shared ...
“As Chair of Senate, I am responsible for the leadership and effective operation of the governing body – both a privilege and a responsibility” A blog by Dr Len O'Hagan, Senior Pro-Chancellor and ...
6:50 p.m. ET After Regeneron revealed early in the day preliminary sales results for Eylea HD, which Evercore ISI analyst Cory Kasimov called “relatively dismal,” CEO Len Schleifer admitted th ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback